BioCentury | Sep 29, 2003
Clinical News

Virocell preclinical data

...vitro and in vivo. The company said the viruses were related to the SARS coronavirus. Virocell Inc....
BioCentury | Oct 14, 2002
Clinical News

BG-777: Phase I

...healthy volunteers. According to the company, BG-777 also was well tolerated and had good pharmacokinetics. Virocell Inc....
BioCentury | Apr 8, 2002
Clinical News

BG-777: Virocell will begin an open-label, dose-escalation Canadian Phase I trial in 20 healthy volunteers.

...category: Immune modulation Target: NA Description: NA Indication: Treat HIV/AIDS Endpoint: Safety and pharmacokinetics Status: Virocell...
Items per page:
1 - 3 of 3
BioCentury | Sep 29, 2003
Clinical News

Virocell preclinical data

...vitro and in vivo. The company said the viruses were related to the SARS coronavirus. Virocell Inc....
BioCentury | Oct 14, 2002
Clinical News

BG-777: Phase I

...healthy volunteers. According to the company, BG-777 also was well tolerated and had good pharmacokinetics. Virocell Inc....
BioCentury | Apr 8, 2002
Clinical News

BG-777: Virocell will begin an open-label, dose-escalation Canadian Phase I trial in 20 healthy volunteers.

...category: Immune modulation Target: NA Description: NA Indication: Treat HIV/AIDS Endpoint: Safety and pharmacokinetics Status: Virocell...
Items per page:
1 - 3 of 3